Bessemer Group
FOLD

Bessemer Group’s Amicus Therapeutics FOLD Stock Holding History

Bessemer Group’s Portfolio FOLD Stock Details FOLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-198
Closed -$2K – 2583
2025
Q3 		$2K Buy
+198
New +$1.41K ﹤0.01% 2316
2024
Q4 		– Sell
-315
Closed -$3K – 2529
2024
Q3 		$3K Buy
+315
New +$3.43K ﹤0.01% 2085
2022
Q2 		– Sell
-300
Closed -$3K – 1922
2022
Q1 		$3K Hold
300
– – ﹤0.01% 1676
2021
Q4 		$3K Hold
300
– – ﹤0.01% 1714
2021
Q3 		$3K Hold
300
– – ﹤0.01% 1571
2021
Q2 		$3K Hold
300
– – ﹤0.01% 1475
2021
Q1 		$3K Buy
+300
New +$4.64K ﹤0.01% 1431

Other funds holding FOLD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Bessemer Group's FOLD Position: Q4 2025 in Review

Bessemer Group sold out of Amicus Therapeutics (FOLD) in Q4 2025, closing a stake of 198 shares — an estimated $2K sold.

Bessemer Group first reported a position in FOLD in Q1 2021 and held it in 7 quarters. The position peaked at $3K in Q3 2024. 332 funds tracked by Wall St. Rank hold FOLD as of Q4 2025.

  • Bessemer Group reported no remaining Amicus Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Bessemer Group sold 198 Amicus Therapeutics shares in Q4 2025, an estimated $2K.
  • Bessemer Group first reported a position in Amicus Therapeutics in Q1 2021 and held it in 7 quarters.
  • Bessemer Group's Amicus Therapeutics position peaked at $3K in Q3 2024.
  • 332 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q4 2025.

Based on Bessemer Group's 13F filing for Q4 2025, filed 5 Feb 2026.